Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 15 studies. IMPAACT 2047: Radiant-Moms Plus DAIDS Number TBD Research Area Tuberculosis Study Status In Development IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment DAIDS Number 35123 Research Area Cure and Immunotherapy Study Status Concluded IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
IMPAACT 2047: Radiant-Moms Plus DAIDS Number TBD Research Area Tuberculosis Study Status In Development
IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment DAIDS Number 35123 Research Area Cure and Immunotherapy Study Status Concluded
IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
